GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials
Zahra Hamedi, Basem M. Mishriky, Victor Okunrintemi, J.R. Powell, Doyle M. Cummings
Abstract
This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Basem M. Mishriky has served on Advisory Board Panel for AstraZeneca and the consulting fees from AstraZeneca paid to the East Carolina University. Doyle M. Cummings has received research grant support from Novo-Nordisk Pharmaceuticals. The other authors declare that there are no conflict of interests. The peer review history for this article is available at https://publons.com/publon/10.1002/DMRR.3436. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Topics & Concepts
MedicineAtrial fibrillationGrant fundingPublic fundingConflict of interestPolitical scienceClinical trialFamily medicineAccountingPublic administrationBusinessInternal medicineLawDiabetes Treatment and ManagementReceptor Mechanisms and SignalingCardiovascular Function and Risk Factors